Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Paclitaxel 15Carboplatin 15Taxes 9Cisplatin 8Topotecan 4Docetaxel 4Filgrastim 3pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Methods 2Gemcitabine 2GEN-1 2Etoposide 2Erlotinib Hydrochloride 2Educational Status 2Early Intervention, Educational 2Chemotherapy, Adjuvant 2vandetanib 1rilotumumab 1oregovomab 1motesanib diphosphate 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1VTX-2337 1Trabectedin 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Fallopian Tube Neoplasms × vandetanib × Clear all
NCT00872989 2016-12-19

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

SWOG Cancer Research Network

Phase 2 Completed
129 enrolled 17 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡